Literature DB >> 7002766

Activation of human B lymphocytes. XII. Differential effects of in vitro cyclophosphamide on human lymphocyte subpopulations involved in B-cell activation.

H C Stevenson, A S Fauci.   

Abstract

The differential effects of in vitro cyclophosphamide (CY) on subpopulations of normal human peripheral blood lymphocytes involved in the pokeweed mitogen-induced plaque-forming cell (PFC) response against sheep red blood cells were examined. It was found that the plaque-forming B cells in this system are sensitive to CY over a wide concentration range including concentrations which have a minimal effect on overall cell viability. Kinetic experiments revealed that CY exerts its inhibitory effect on the PFC response only if added very early in culture. Thus, it appears that in vitro CY must exert its inhibitory influence on an early phase of polyclonal B-cell activation. When T-cell enriched (TCE) populations were incubated overnight with high concentration CY and then added back in co-culture to fresh autologous B cells, significant enhancement of PFC responses was observed suggesting a selective inhibition or elimination of a regulatory suppressor cell population found in TCE lymphocyte preparations. Helper T cells are relatively resistant to the inhibitory actions of CY. Thus, human B cells appear to be most sensitive to CY, followed in sensitivity by the suppressor cell populations in the T-cell fraction with relative resistance of the helper T cells. These observations have direct relevance in understanding the mechanisms of selective action of CY on normal human lymphocyte subpopulations with possible application to disease states in man.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7002766      PMCID: PMC1457815     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  26 in total

1.  Cyclophosphamide and lymphocyte subpopulations in Wegener's granulomatosis.

Authors:  A S Fauci; D C Dale; S M Wolff
Journal:  Arthritis Rheum       Date:  1974 Jul-Aug

2.  Immune response of patients with rheumatoid arthritis during cyclophosphamide treatment.

Authors:  J E Curtis; J T Sharp; M D Lidsky; E M Hersh
Journal:  Arthritis Rheum       Date:  1973 Jan-Feb

3.  Studies on the effect of cyclophosphamide on T and B lymphocytes in the blood, lymph nodes, and thymus of normal guinea pigs.

Authors:  P A Revell
Journal:  Int Arch Allergy Appl Immunol       Date:  1974

4.  Enzymatic basis of cyclophosphamide activation by hepatic microsomes of the rat.

Authors:  J L Cohen; J Y Jao
Journal:  J Pharmacol Exp Ther       Date:  1970-08       Impact factor: 4.030

5.  Reversal of immunological tolerance by cyclophosphamide through inhibition of suppressor cell activity.

Authors:  L Polak; J L Turk
Journal:  Nature       Date:  1974-06-14       Impact factor: 49.962

6.  Wegener's granulomatosis: studies in eighteen patients and a review of the literature.

Authors:  A S Fauci; S M Wolff
Journal:  Medicine (Baltimore)       Date:  1973-11       Impact factor: 1.889

7.  Selective depletion of lymphoid tissue by cyclophosphamide.

Authors:  J L Turk; L W Poulter
Journal:  Clin Exp Immunol       Date:  1972-02       Impact factor: 4.330

8.  Effect of cyclophosphamide upon the immune response in Wegener's granulomatosis.

Authors:  A S Fauci; S M Wolff; J S Johnson
Journal:  N Engl J Med       Date:  1971-12-30       Impact factor: 91.245

9.  Cyclophosphamide suppression of established cell-mediated immunity. Quantitative vs. qualitative changes in lymphocyte populations.

Authors:  J E Balow; D L Hurley; A S Fauci
Journal:  J Clin Invest       Date:  1975-07       Impact factor: 14.808

10.  Augmentation of delayed-type hypersensitivity by doses of cyclophosphamide which do not affect antibody responses.

Authors:  P W Askenase; B J Hayden; R K Gershon
Journal:  J Exp Med       Date:  1975-03-01       Impact factor: 14.307

View more
  15 in total

1.  Rituximab versus cyclophosphamide for ANCA-associated vasculitis.

Authors:  John H Stone; Peter A Merkel; Robert Spiera; Philip Seo; Carol A Langford; Gary S Hoffman; Cees G M Kallenberg; E William St Clair; Anthony Turkiewicz; Nadia K Tchao; Lisa Webber; Linna Ding; Lourdes P Sejismundo; Kathleen Mieras; David Weitzenkamp; David Ikle; Vicki Seyfert-Margolis; Mark Mueller; Paul Brunetta; Nancy B Allen; Fernando C Fervenza; Duvuru Geetha; Karina A Keogh; Eugene Y Kissin; Paul A Monach; Tobias Peikert; Coen Stegeman; Steven R Ytterberg; Ulrich Specks
Journal:  N Engl J Med       Date:  2010-07-15       Impact factor: 91.245

Review 2.  Experience with rituximab in the treatment of antineutrophil cytoplasmic antibody associated vasculitis.

Authors:  Jeremy M Clain; Rodrigo Cartin-Ceba; Fernando C Fervenza; Ulrich Specks
Journal:  Ther Adv Musculoskelet Dis       Date:  2014-04       Impact factor: 5.346

3.  Kinetics of Cyclophosphamide Metabolism in Humans, Dogs, Cats, and Mice and Relationship to Cytotoxic Activity and Pharmacokinetics.

Authors:  Dominique A Ramirez; Keagan P Collins; Allister E Aradi; Katherine A Conger; Daniel L Gustafson
Journal:  Drug Metab Dispos       Date:  2018-12-19       Impact factor: 3.922

4.  Pro: Should all patients with anti-neutrophil cytoplasmic antibody-associated vasculitis be primarily treated with rituximab?

Authors:  Ulrich Specks
Journal:  Nephrol Dial Transplant       Date:  2015-05-21       Impact factor: 5.992

5.  Cancer chemotherapeutics as immunomodulators.

Authors:  F Spreafico; A Vecchi; F Colotta; A Montovani
Journal:  Springer Semin Immunopathol       Date:  1985

6.  In-vitro analysis of defective IgA production in selective IgA deficiency in childhood.

Authors:  N Shinomiya; J Yata
Journal:  Clin Exp Immunol       Date:  1985-12       Impact factor: 4.330

7.  Effects of 3,3',4,4'-tetrachloroazoxybenzene on selected immune parameters of the mouse.

Authors:  M R Bleavins; R D Hinsdill; J R Hochstein; M T Hsia
Journal:  Arch Environ Contam Toxicol       Date:  1985-11       Impact factor: 2.804

8.  Interaction of pokeweed mitogen with monocytes in the activation of human lymphocytes.

Authors:  H C Stevenson; P J Miller; M J Waxdal; B F Haynes; C A Thomas; A S Fauci
Journal:  Immunology       Date:  1983-08       Impact factor: 7.397

9.  Efficacy of remission-induction regimens for ANCA-associated vasculitis.

Authors:  Ulrich Specks; Peter A Merkel; Philip Seo; Robert Spiera; Carol A Langford; Gary S Hoffman; Cees G M Kallenberg; E William St Clair; Barri J Fessler; Linna Ding; Lisa Viviano; Nadia K Tchao; Deborah J Phippard; Adam L Asare; Noha Lim; David Ikle; Brett Jepson; Paul Brunetta; Nancy B Allen; Fernando C Fervenza; Duvuru Geetha; Karina Keogh; Eugene Y Kissin; Paul A Monach; Tobias Peikert; Coen Stegeman; Steven R Ytterberg; Mark Mueller; Lourdes P Sejismundo; Kathleen Mieras; John H Stone
Journal:  N Engl J Med       Date:  2013-08-01       Impact factor: 91.245

10.  Long-term cyclophosphamide treatment in rheumatoid patients: effects on serum sulphydryl levels, technetium index, ESR and clinical response.

Authors:  M G Grimaldi
Journal:  Br J Clin Pharmacol       Date:  1981-10       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.